Encora Therapeutics Completes ULTRE Trial for Wrist-Worn Essential Tremor Device
Encora Therapeutics is excited to announce the successful completion of the ULTRE (Upper Limb Tremor Reduction in Essential Tremor) clinical trial. The study assessed the safety, tolerability, and effectiveness of Encora’s innovative wrist-worn stimulation device for individuals with essential tremor…
Vir Biotechnology Announces Positive Chronic Hepatitis Delta Trial Data and Phase 3 Program Launch
Vir Biotechnology, Inc. (NASDAQ:VIR) today revealed positive results from the SOLSTICE Phase 2 clinical trial evaluating its investigational combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta (CHD). The trial, which included both monotherapy and combination therapy…
HistoSonics® Enrolls First Patients in BOOMBOX Master Study
HistoSonics, the developer of the Edison® Histotripsy System, has announced the enrollment of the first patients in its novel BOOMBOX study, a prospective master protocol designed to assess the real-world application of histotripsy for treating liver tumors. This post-market study…
Lobe Sciences and Alera Pharma Announce Second U.S. Patent Allowance for Conjugated Psilocin™
Lobe Sciences, Ltd. (CSE: LOBE, OTCQB: LOBEF) and Alera Pharma, Inc. today announced the receipt of a second patent allowance for their Conjugated Psilocin™ technology. The patent, titled “Stable Psilocin Salts, Esters, and Conjugates and Uses Thereof,” covers compositions that…
SOLVD Health Launches 5-Year Post-Approval Study on AvertD® Genetic Test
SOLVD Health, a patient intelligence company focused on precision solutions to improve health outcomes, has launched a comprehensive post-approval study for AvertD®, the first FDA-approved genetic test to assess the risk of opioid use disorder (OUD). The study will build…
Supercomputing 2024: ALAFIA Unveils Personal Supercomputers for Precision Medicine & AI
Alafia AI, Inc. (“ALAFIA”), a leader in omics computing and precision medicine, is today unveiling an expansion of its high-performance computing (HPC) product line to address the growing demand for scalable, heterogeneous computing in the biopharmaceutical and application development industries.…
Aurinia Praises 2024 ACR Guidelines on Lupus Nephritis Management
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) commended the American College of Rheumatology (ACR) for its newly released 2024 evidence-based guidelines on the screening, treatment, and management of lupus nephritis (LN). The updated guidelines emphasize the urgent need for effective treatments to…
RheaVita Partners with IMA Life to Accelerate Tech Development and Growth
RheaVita, a leader in controlled, continuous freeze-drying technology for biopharmaceuticals, has entered into a strategic partnership with IMA Life, a global leader in advanced aseptic pharmaceutical production solutions and one of the three pharma divisions of IMA Group. The partnership…
CapeStart Launches MadeAi™: GenAI Platform for Life Sciences
At the ISPOR Europe 2024 Conference, CapeStart, Inc. unveiled MadeAi™, a generative AI-powered platform designed to revolutionize the synthesis of clinical information. The platform’s first solution, MadeAi-LR, enhances the efficiency of systematic literature reviews (SLRs), clinical evidence reports (CERs), meta-research,…
BrightHeart Gets FDA Approval for AI-Powered Prenatal Fetal Heart Ultrasound
BrightHeart, an innovator in AI technology for obstetrics and pediatric cardiology, has received FDA 510(k) clearance for its first AI-driven software, which aims to revolutionize prenatal ultrasound evaluations of the fetal heart. This breakthrough comes at a critical time, as…
$2.4M Fast Track Grant Awarded for PSMA-Targeted Prostate Cancer Drug
Cancer Targeted Technology (CTT), a Seattle-based biotechnology company focused on cancer diagnostics and therapies, announced that the National Cancer Institute has awarded the Phase I portion ($400K) of a fast-track Phase I/II Small Business Innovation Research (SBIR) grant to support…
Adicet Bio Presents Biomarker Data for Off-the-Shelf CAR T Therapy at ACR Convergence 2024
Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that clinical biomarker data from the ADI-001 Phase 1 GLEAN trial will be presented in…